A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects
Status:
Completed
Trial end date:
2020-12-04
Target enrollment:
Participant gender:
Summary
This is a single-dose, open-label, phase I clinical study evaluating the PK of hetrombopag in
subjects with mild hepatic impairment (Child-Pugh Class A), subjects with moderate hepatic
impairment (Child-Pugh Class B), as well as age-, weight-, and gender-matched subjects with
normal hepatic function.